Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 21;45(19):1733-1737.
doi: 10.1093/eurheartj/ehae225.

Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial

Gregory Y H Lip  1   2 , Julius Nikorowitsch  3   4 , Susanne Sehner  5 , Nina Becher  3   4 , Emanuele Bertaglia  6 , Carina Blomstrom-Lundqvist  7   8 , Axel Brandes  9 , Vincent Beuger  10 , Melanie Calvert  11   12 , A John Camm  13 , Gregory Chlouverakis  14 , Gheorghe-Andrei Dan  15 , Wolfgang Dichtl  16 , Hans Christoph Diener  17 , Alexander Fierenz  5 , Andreas Goette  18   19 , Joris R de Groot  20 , Astrid Hermans  21 , Andrzej Lubinski  22 , Eloi Marijon  23 , Béla Merkely  24 , Lluís Mont  25   26   27 , Ann-Kathrin Ozga  5 , Kim Rajappan  28 , Andrea Sarkozy  29 , Daniel Scherr  30 , Renate B Schnabel  3   4 , Ulrich Schotten  10   21 , Emmanuel Simantirakis  31 , Tobias Toennis  3   4 , Panos Vardas  31   32 , Dan Wichterle  33 , Antonia Zapf  5 , Paulus Kirchhof  3   4   10
Affiliations

Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial

Gregory Y H Lip et al. Eur Heart J. .
No abstract available

Keywords: Anticoagulation; Atrial fibrillation; Atrial high-rate episodes; Bleeding; CHA2DS2-VASc score; Device-detected atrial fibrillation; Kidney function; NOAH-AFNET 6; Stroke.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) CONSORT flow chart of pre-specified secondary analysis of the NOAH-AFNET 6 trial. Displayed are the analysis population, the number of patients experiencing a primary or safety outcome, and the event rate for each outcome in each group. (B) Stroke, systemic embolism, or cardiovascular death (primary outcome), major bleeding or death (safety outcome), ischaemic stroke and major bleeding event rate estimates per CHA2DS2-VASc score and treatment group (edoxaban orange on the left, placebo blue on the right). The LOWESS (locally weighted scatterplot smoothing) curves show the dependence of the probability of an event on the CHA2DS2-VASc score. Each dot represents a patient. Patients with events are shown at the top and patients without events are shown at the bottom. (C) Forest plots of the major predictors of efficacy (left) and safety (right) outcomes in the entire study population (n = 2534). Grey shaded arrows indicate efficacy predictors with P-values > .05. Orange curves show LOWESS-estimated event rates with edoxaban, blue curves show LOWESS-estimated event rates without anticoagulation. AF, atrial fibrillation; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ER, event rate per 100 patient-years follow-up; ESC, European Society of Cardiology; HR, hazard ratio; TIA, transient ischaemic attack
See this image and copyright information in PMC

References

    1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. . 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498. 10.1093/eurheartj/ehaa612 - DOI - PubMed
    1. Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, et al. . Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023;389:1167–79. 10.1056/NEJMoa2303062 - DOI - PubMed
    1. Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. . Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024;390:107–17. 10.1056/NEJMoa2310234 - DOI - PubMed
    1. Becher N, Toennis T, Bertaglia E, Blomstrom-Lundqvist C, Brandes A, Cabanelas N, et al. . Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥ 24 h. Eur Heart J 2024;45:837–49. 10.1093/eurheartj/ehad771 - DOI
    1. McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L, et al. . Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation 2024;149:981–8. 10.1161/CIRCULATIONAHA.123.067512 - DOI - PubMed